Crystalline forms of Prasugrel salts
Salts of prasugrel were prepared including, for example, crystalline forms of prasugrel hydrobromide. These salts are useful, for example, in medicaments that inhibit the aggregation of platelets.
1. A crystalline Form I of Prasugrel hydrobromide according to formula I,
characterized by:
an X-ray powder diffraction pattern having peaks at 7.8, 14.4, 16.9, 22.0 and 25.1 degrees two theta±0.2 degrees two theta;
a solid-state 13 C NMR spectrum having peaks at 7.1, 11.2, 63.6, 123.7 and 203.4±0.2 ppm; or a combination thereof.
2. A crystalline Form IA of Prasugrel hydrobromide according to formula I,
characterized by an X-ray powder diffraction pattern having peaks at 7.9, 8.1, 13.5, 14.6 and 25.2 degrees two theta±0.2 degrees two theta.
3. The crystalline Form I of Prasugrel hydrobromide according to claim 1 , further characterized by an XRPD pattern substantially as depicted in FIG. 6 and/or by a solid-state 13C NMR spectrum substantially as depicted in FIG. 23 .
4. The crystalline Form IA of Prasugrel hydrobromide according to claim 2 , further characterized by an XRPD pattern substantially as depicted in FIG. 11 .
5. A pharmaceutical composition comprising at least one crystalline form according to any of claims 1 , 2 and 3 - 4 , and at least one pharmaceutically acceptable excipient.
6. A method of producing a pharmaceutical composition comprising combining at least one crystalline form according to any of claims 1 , 2 and 3 - 4 , and at least one pharmaceutically acceptable excipient.
7. The crystalline Form I of Prasugrel hydrobromide according to claim 1 , wherein the crystalline Form I is anhydrous.
8. The crystalline Form IA of Prasugrel hydrobromide according to claim 2 , wherein the crystalline Form IA is anhydrous.
9. The crystalline Form I of Prasugrel hydrobromide according to claim 1 wherein the X-ray powder diffraction pattern has additional peaks at 13.5, 19.9, 23.6, 27.0 and 29.7 degrees two theta±0.2 degrees two theta.
10. The crystalline Form IA of Prasugrel hydrobromide according to claim 2 wherein the X-ray powder diffraction pattern has additional peaks at 16.8, 21.4, 23.7, 24.9 and 27.2 degrees two theta±0.2 degrees two theta.